Skip to content
Review Open access

Advances in Multi-Omics Research on Post-Stroke Depression: From Molecular Mechanisms to Therapeutic Strategies

Oct 2026 · Neuropsychiatric Disease and Treatment · Vol 22 · 0 citations · 92 references
Medicine

TL;DR

Overall, multi-omics studies have provided new insights into the molecular basis of PSD and facilitated the identification of potential biomarkers and therapeutic targets, however, their clinical utility requires further evaluation through standardized cohorts and validation studies.

Abstract

Abstract Post-stroke depression (PSD) is a common neuropsychiatric complication after stroke and has a substantial impact on functional recovery, quality of life, and long-term outcomes. Because stroke-related manifestations, including aphasia, cognitive impairment, fatigue, and somatic symptoms, overlap with depressive symptoms, the clinical identification of PSD still largely relies on symptom assessment and clinical interviews, resulting in delayed diagnosis and intervention in some patients. Recent studies indicate that the development of PSD is not driven by a single pathological process but involves multiple mechanisms, including neuroinflammation, neural network alterations, dysfunction of the neurovascular unit, disturbances in energy and lipid metabolism, imbalance of the microbiota–gut–brain axis, and psychosocial factors following brain injury. The advancement of multi-omics technologies has provided new approaches for investigating the biological mechanisms underlying PSD. This review systematically summarizes recent progress in the application of multi-omics approaches in PSD research, focusing on molecular alterations identified across different omics platforms and potential biomarkers. Furthermore, the role of the hypothalamic–pituitary–adrenal (HPA) axis in stress response regulation and PSD development is discussed within the context of neuro–immune–metabolic interactions. Overall, multi-omics studies have provided new insights into the molecular basis of PSD and facilitated the identification of potential biomarkers and therapeutic targets. However, their clinical utility requires further evaluation through standardized cohorts and validation studies.

Read PDF

Similar papers

Review Open access Sep 2026

Treatment-Resistant Depression: A Literature Review of Innovative and Emerging Treatment Strategies

Introduction and objective: Major depressive disorder (MDD) is a heterogeneous psychiatric condition characterized by affective, cognitive and somatic symptoms that considerably impair daily functioning. It is defined clinically by prolonged low mood, diminished interest or pleasure, and a range of associated disturban...

Maciej Kisielewski, Natalia Fidut, Jakub Skrzypek et al. · 0 citations
Review Open access Sep 2026

Neurobiological mechanisms and brain network dysfunction in major depressive disorder: an integrative review

Major depressive disorder (MDD) is a prevalent and disabling psychiatric disorder characterized by persistent mood disturbances, cognitive impairments, and significant systemic consequences. Despite its substantial clinical burden, diagnosis remains challenging because current approaches rely largely on subjective symp...

D. Iskakova, Burcu Yener, A. Kamzanova et al. · 0 citations
Review Open access Oct 2026

Neuroplasticity Biomarkers and Neurotransmitter Modulation in Post-Ischemic Stroke Rehabilitation: A Narrative Review

Background/Objectives: Recovery after stroke is a complex process involving structural and functional reorganization of the nervous system. Neuroplasticity plays a key role in functional recovery, while biomarkers and neurotransmitter systems may reflect or modulate the biological processes underlying rehabilitation an...

Karolina Szymczak-Kumoniewska, Angela Dziedzic, Joanna Saluk et al. · 0 citations
Review Open access Sep 2026

Advances in the management of depression in Parkinson's disease: A narrative review on vortioxetine, hyperbaric oxygen, and physical activity.

Depression is one of the most prevalent and disabling non-motor symptoms of Parkinson's disease (PD), yet current treatments remain suboptimal, with many patients experiencing incomplete response to standard antidepressants. Growing evidence highlights the need for multimodal approaches addressing the complex neurobiol...

Irene Mesquita, B. Araújo, C. Soares-Guedes et al. · 0 citations
Open access Jul 2026

What is new in delirium: A vascular etiology outlook

Abstract Emerging studies have highlighted the vascular contributions to cognitive impairment and dementia (VCID), especially in the context of neurodegenerative disorders that cause cognitive decline (i.e., Alzheimer's disease and related dementias [ADRD]). More recent research on perioperative neurocognitive disorder...

N. Terrando, Mervyn Maze, Ting Yang · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.